Cancer Causes Control:血清IL-16和前列腺癌风险的前瞻性评估

2018-04-10 AlexYang MedSci原创

性传播感染和慢性炎症与前列腺癌风险的增加相关。炎症调控因子,比如细胞因子和自由基,被假设在其中具有作用。最近,有研究人员为了探索炎症在前列腺癌风险中的作用,调查了诊断前血清IL-16水平与前列腺癌风险之间的相关性。研究发现,尽管IL-16与前列腺癌之间在白种人之间没有发现相关性(p=0.27),但是IL-16增加时(OR3rd vs. 1st tertile=1.37, 95% CI 1.04-1

性传播感染和慢性炎症与前列腺癌风险的增加相关。炎症调控因子,比如细胞因子和自由基,被假设在其中具有作用。最近,有研究人员为了探索炎症在前列腺癌风险中的作用,调查了诊断前血清IL-16水平与前列腺癌风险之间的相关性。

研究发现,尽管IL-16与前列腺癌之间在白种人之间没有发现相关性(p=0.27),但是IL-16增加时(OR3rd vs. 1st tertile=1.37, 95% CI 1.04-1.81, ptrend=0.02),能够观察到高等级前列腺癌风险的显著增加,即格林森不小于7(Phet=0.02)。研究人员同时还发现了IL-16与淋病之间显著的互作(p=0.04)。在白种人且患有淋病的男性中,IL-16水平的提高与前列腺癌风险的增加相关(OR3rd vs. 1st tertile=3.64, 95% CI 1.14-11.6),但是在没有淋病历史的男性中没有发现上述相关性(OR3rd vs. 1st tertile=1.06, 95% CI 0.83-1.34)。另外,在非裔美国人之间没有发现相关性。

最后,研究人员指出,他们的研究发现了更高的诊断前IL-16水平与高等级疾病风险的增加相关的证据,支持了性传播炎症也许能够增加前列腺癌风险的论点。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022562, encodeId=5986202256261, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Nov 15 00:43:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061733, encodeId=78a42061e33ac, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Nov 26 07:43:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006430, encodeId=36e32006430a1, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Sep 07 05:43:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508211, encodeId=4d22150821142, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569730, encodeId=677e1569e3080, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022562, encodeId=5986202256261, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Nov 15 00:43:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061733, encodeId=78a42061e33ac, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Nov 26 07:43:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006430, encodeId=36e32006430a1, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Sep 07 05:43:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508211, encodeId=4d22150821142, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569730, encodeId=677e1569e3080, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-11-26 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022562, encodeId=5986202256261, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Nov 15 00:43:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061733, encodeId=78a42061e33ac, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Nov 26 07:43:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006430, encodeId=36e32006430a1, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Sep 07 05:43:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508211, encodeId=4d22150821142, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569730, encodeId=677e1569e3080, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022562, encodeId=5986202256261, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Nov 15 00:43:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061733, encodeId=78a42061e33ac, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Nov 26 07:43:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006430, encodeId=36e32006430a1, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Sep 07 05:43:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508211, encodeId=4d22150821142, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569730, encodeId=677e1569e3080, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 jjjiang0202
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022562, encodeId=5986202256261, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Nov 15 00:43:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061733, encodeId=78a42061e33ac, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Nov 26 07:43:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006430, encodeId=36e32006430a1, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Sep 07 05:43:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508211, encodeId=4d22150821142, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569730, encodeId=677e1569e3080, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Apr 12 10:43:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 dongjia2015

相关资讯

JAMA Oncol:前列腺癌临床试验疗效评价指标的探索:OS可以被替代吗?

观察时间较OS短、并且能够反映是否存在临床获益的主要评价指标,目前在晚期转移性去势抵抗前列腺癌(mCPRC)患者的相关新药研发临床试验中还相对比较缺乏。基于此,由前列腺癌临床试验工作组(PCWG2)提出了放射影像学无进展生存率(rPFS)这一指标。那么这个指标在实际应用中效果如何,它能否成为一个OS的替代指标呢?下面跟随小编一探究竟。

Nat Genet:前列腺癌中致癌驱使因子的研究

前列腺癌综合的基因组特征分析鉴定了许多基因中的复发性变异,这些基因参与了雄激素信号途径、DNA修复和PI3K信号途径以及其他相关过程。然而,更大的和统一的基因组分析也许能够在更低的频率上鉴定另外的复发性突变的基因。最近,有研究人员对来自1013名前列腺癌样本的外显子组测序数据进行了集中和一致性的分析。研究人员鉴定和确认了一类新的E26转录因子(ETS)融合阴性肿瘤,是通过表观调控因子的变异以及在之

JCO:前列腺癌患者放疗新技术的选择

放疗在局部前列腺癌患者的治疗中占有举足轻重的作用。目前新的放疗技术包括立体定向放疗技术以及质子放疗,相对于调强放疗技术对患者带来的放疗损伤究竟是否有降低以及新技术需要的成本究竟是否有显著增加?想要得到答案,请您跟随小编一探究竟。

Clin Transl Oncol:Nur77的抑制能够促进前列腺癌细胞雄激素阻断诱导的细胞浸润

雄激素阻断疗法(ADT)是晚期前列腺癌的标准治疗方法。然而,一些研究阐释了当抑制某种类型的前列腺癌细胞的生长,ADT就能够促进浸润。最近,有研究人员探索了Nur77,一个孤儿核受体,在ADT后对前列腺癌细胞浸润的影响。研究发现,AR和Nur77在前列腺癌病人中均高度表达。Nur77在NCI-H660前列腺癌细胞系中,在转录水平上受AR信号的正调控。AR拮抗剂,比卡鲁胺和MDV3100处理能够导致前

Nature Chem:另辟蹊径,借助液体活检改善前列腺癌的治疗

根据世界卫生组织的统计,前列腺癌是造成全球男性死亡的第五大原因。尽管目前已有一些可行的治疗方案,但许多前列腺癌患者对一线治疗方法无响应。对此,多伦多大学的研究人员开发出一种液体活检技术,以确定哪些患者可能无响应。

Ann Behav Med:锻炼可以缓解激素疗法治疗前列腺癌产生的副作用

雄激素限制疗法是治疗前列腺癌的有效手段,而且随着一系列激素疗法的应用,越来越多的男性患者选择使用上述疗法。但这回带来一些负面的效应:抑制雄性荷尔蒙,包括睾酮,将会在限制肿瘤生长的同时减小肌肉维度以及强壮程度,这会使得男性患其它疾病,例如心脏病以及糖尿病的风险上升。